CNS Pharmaceuticals (CNSP) Cash from Investing Activities (2019 - 2024)
CNS Pharmaceuticals' (CNSP) quarterly Cash from Investing Activities came in at -$4188.0 in Q4 2024, down 94.16% YoY from -$71694.6 in Q1 2024, and down 94.16% on a QoQ basis from -$2157.0 in Q4 2023.
CNS Pharmaceuticals (CNSP) Cash from Investing Activities (2019 - 2024) Analysis & Trends
CNS Pharmaceuticals (CNSP) has 6 years of Cash from Investing Activities data on file, last reported at -$4188.0 in Q4 2024.
- Quarterly Cash from Investing Activities fell 94.16% year-over-year to -$4188.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$8088.0 (down 49.39% YoY) and the FY2025 annual result came in at -$18175.0, down 333.98% from the prior year.
- Cash from Investing Activities retreated to -$4188.0 in Q4 2024, from -$2157.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $1.0 in Q4 2022 to a low of -$11535.0 in Q2 2020.
- A 5-year average of -$3620.4 and a median of -$2533.0 in 2022 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities soared 100.05% — and 2023, when it sank 215800.0%.
- Tracing CNSP's Cash from Investing Activities over 5 years: stood at -$11535.0 in 2020, then soared by 82.0% to -$2076.0 in 2021, then soared by 100.05% to $1.0 in 2022, then slumped by 215800.0% to -$2157.0 in 2023, then sank by 94.16% to -$4188.0 in 2024.
- The last three Cash from Investing Activities figures came in at -$4188.0 (Q4 2024), -$2157.0 (Q4 2023), and -$1744.0 (Q3 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | CNS Pharmaceuticals | 2.65 Mn | -4.55 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -4,188.00 |
| Dec 31, 2024 | -4,188.00 |
| Dec 31, 2023 | -2,157.00 |
| Dec 31, 2023 | -2,157.00 |
| Sep 30, 2023 | -1,744.00 |
| Sep 30, 2023 | -1,744.00 |
| Dec 31, 2022 | 1.00 |
| Dec 31, 2022 | 1.00 |
| Sep 30, 2022 | -1,514.00 |
| Sep 30, 2022 | -1,514.00 |
| Jun 30, 2022 | -2,909.00 |
| Jun 30, 2022 | -2,909.00 |
| Dec 31, 2021 | -2,076.00 |
| Dec 31, 2021 | -2,076.00 |
| Mar 31, 2021 | -3,672.00 |
| Mar 31, 2021 | -3,672.00 |
| Jun 30, 2020 | -11,535.00 |
| Jun 30, 2020 | -11,535.00 |
| Mar 31, 2020 | -6,410.00 |
| Mar 31, 2020 | -6,410.00 |